Compositions and methods of treating cancer with chimeric antigen receptors
AssigneeAstraZeneca AB
InventorsGORDON MOODY, MARIA LETIZIA GIARDINO-TORCHIA, MICHAEL GLEN OVERSTREET, RYAN GILBRETH
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
Claims34
An isolated nucleic acid sequence encoding
- a) a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen;
- and
- b) an armoring molecule, wherein the armoring molecule counters immunosuppression of a cell in a tumor microenvironment when expressed on a surface of the cell.
The isolated nucleic acid sequence according to any of the preceding claims further comprising a transmembrane domain, a costimulatory domain, and a signal domain.
The isolated nucleic acid sequence according to any of the preceding claims further comprising further comprising a hinge/spacer domain.
A vector, comprising a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an antigen-binding domain specific for a cell surface antigen and an armoring molecule, wherein the nucleic acid sequence comprises SEQ ID NO:
- 46.
A cell, comprising:
- a nucleic acid sequence encoding a chimeric antigen receptor (CAR), and
- a TGFβRIIDN armoring molecule expressed on a surface of the cell.
A cell, comprising:
- an anti-GPC3 chimeric antigen receptor (CAR) comprising an antigen binding domain, wherein the antigen binding domain comprises an antibody, Fab, or an scFv comprising a heavy chain variable region (VH) and a light chain variable region (VL),
- wherein the VH comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 37, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 38, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 39, and
- wherein the VL comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 40 or SEQ ID NO:
- 43, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 41 or SEQ ID NO:
- 44, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 42 or SEQ ID NO:
- 45;
- and
- a TGFβRIIDN armoring molecule.
A method of treating cancer, comprising:
- administering to a subject in need thereof a cell, wherein the cell comprises
- a) a chimeric antigen receptor (CAR) specific for a cell surface antigen, and
- b) an armoring molecule, wherein the armoring molecule counters immunosuppression of the cell in a tumor microenvironment of the cancer.
The method of claim 31, wherein the cell is an autologous cell.
Dependencies are inferred from the claim text.